Study of Cardiometabolic Disease, Insulin Resistance, and Placental Health in Pregnant Women at Risk

What this Trial Is About

Cardiometabolic diseases like pre-eclampsia and gestational diabetes affect about 15% of pregnancies and can cause serious problems for mothers and newborns. This research aims to understand how insulin resistance and maternal fat metabolism relate to these conditions. It focuses on early pregnancy and looks beyond typical glucose tests to include various metabolic factors and placental function, offering a broader view of disease development during pregnancy. Pregnant individuals at risk for cardiometabolic disease will be observed during two visits one between 12 and 18 weeks and another between 26 and 30 weeks of pregnancy. During these visits, fasting blood tests will measure insulin, glucose, lipid metabolism, and other metabolic markers. Additional assessments include indirect calorimetry, body composition, and neonatal measures. The study also examines placental pathology to understand the maternal, fetal, and placental interactions in disease development. Participants will attend two study visits where fasting blood samples and metabolic tests are collected. Researchers will measure insulin resistance, lipid oxidation rates, resting metabolic rates, various blood lipids, and glucose levels. Survey data and body composition will also be gathered. The study monitors maternal and neonatal outcomes related to cardiometabolic health, with the goal of identifying early markers and mechanisms. Participation lasts through these visits during pregnancy, with no treatment interventions involved.

Cardiometabolic Disease and Substrate Metabolism